Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

HDSN vs CCRN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HDSN Captures Overall Composite Edge (53.2 HOLD vs 52.5 HOLD), While CCRN Leads 4–2 on Growth & Valuation Pillars

HDSN Overall Winner 6-Pillar Tally: HDSN 2 – 4 CCRN Matrix Metrics: HDSN 6 – 4 CCRN

As of Nov 16, 2026, Hudson Technologies Inc (HDSN) captures the overall head-to-head institutional edge over Cross Country Healthcare Inc (CCRN) on higher Unified Composite conviction (53.2/100 HOLD vs. 52.5/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while CCRN wins 4–2 across the 6-pillar growth and valuation breakdown. HDSN trades at $4.25 (25.9x Forward P/E, 2.0% operating margin) versus CCRN at $13.25 (47.3x Forward P/E, -0.8% operating margin).

  • Growth vs. Quality Trade-Off: HDSN earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. CCRN 52.5/100 HOLD) and 1.32β · 68% Vol risk profile, whereas CCRN leads top-line expansion (-17.8% YoY revenue growth, 12.61x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: HDSN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.9); meanwhile CCRN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 76.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HDSN vs CCRN
HDSN NASDAQ Head-to-Head Winner
Hudson Technologies Inc
Wholesale-Machinery, Equipment & Supplies
$4.25
-3.52% 1D
Market Cap $186.5M
TTM Revenue $242M
Forward P/E 25.9x
Beta / 30D Vol 1.32β · 68% Vol
Unified Composite Score
53.2 / 100 HOLD
Tech 67.0 Fund 65.0 Flow 55.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.3%), weak momentum, RSI 35
RSI-14: 34.9 · SMA20: $4.68 · SMA50: $4.99
CCRN NASDAQ
Cross Country Healthcare Inc
Services-Help Supply Services
$13.25
+0.08% 1D
Market Cap $427.7M
TTM Revenue $1.00B
Forward P/E 47.3x
Beta / 30D Vol 0.50β · 2% Vol
Unified Composite Score
52.5 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.7% over 20 days), RSI 76
RSI-14: 76.1 · SMA20: $13.21 · SMA50: $13.16

6-Pillar Scorecard Institutional Category Breakdown (HDSN 2 – 4 CCRN)

Columns: Metric · HDSN · CCRN
1. Valuation Multiples HDSN
Forward P/E 25.9x 47.3x
Trailing P/E 16.5x 126.6x
PEG Ratio 0.29x 12.61x
EV / Revenue 0.6x 0.3x
2. Growth & Scale CCRN
Revenue Growth (YoY) -19.7% -17.8%
Earnings Growth (YoY) -82.0% -78.5%
TTM Revenue (USD) $242M $1.00B
Market Cap $186.5M $427.7M
3. Profitability & Quality HDSN
Gross Margin 21.0% 20.2%
Operating Margin 2.0% -0.8%
Net Profit Margin -0.5% -9.8%
Return on Equity (ROE) -0.5% -27.0%
4. Balance Sheet & Cash Flow CCRN
Cash Generation (TTM) -$32M $40M
Cash Flow Margin -13.0% 4.0%
Net Cash / Leverage $31M Net Cash $104M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CCRN
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 79.1% (15th %ile) 11.1% (4th %ile)
Put/Call OI Skew N/A 0.76x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat CCRN
OpEx & R&D Intensity 19.0% of Rev ($46M) 21.0% of Rev ($210M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Specialty Chemicals Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HDSN (6) vs CCRN (4)
Institutional Metric HDSN CCRN Criterion Row Edge
Market Capitalization
Scale
$186.5M $427.7M Larger Scale CCRN
Trailing P/E Ratio
Valuation
16.5x 126.6x Lower Multiple HDSN
Forward P/E Ratio
Valuation
25.9x 47.3x Lower Multiple HDSN
Revenue Growth (YoY)
Growth
-19.7% -17.8% Higher Growth CCRN
Operating Margin (TTM)
Profitability
2.0% -0.8% Higher Margin HDSN
Net Profit Margin
Profitability
-0.5% -9.8% Higher Margin HDSN
Return on Equity (ROE)
Capital Efficiency
-0.5% -27.0% Higher ROE HDSN
52-Week Range Position
Momentum
6% ($4–$8) 77% ($7–$15) Stronger Trend CCRN
Beta / 30D Volatility
Risk Regime
1.32β · 68% Vol 0.50β · 2% Vol Lower Realized Risk CCRN
Unified Institutional Score
Composite Signal
53.2 / 100 (HOLD) 52.5 / 100 (HOLD) Higher Composite HDSN
Trailing 12M Revenue (USD)
Operating Scale
$242M $1.00B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
21.0% 20.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.29x PEG · 0.6x EV/Rev 12.61x PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M ($31M Net Cash) $40M ($104M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HDSN +7.92 pp
HDSN: +8.53% · CCRN: +0.61%
3M Horizon CCRN +38.01 pp
HDSN: -3.63% · CCRN: +34.38%
6M Horizon CCRN +63.09 pp
HDSN: -17.65% · CCRN: +45.44%
1Y Horizon CCRN +32.83 pp
HDSN: -10.93% · CCRN: +21.9%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period HDSN Revenue CCRN Revenue HDSN Op. Margin CCRN Op. Margin Margin Leader
FY2018 $170M $820M -25.6% -1.6% CCRN
FY2019 $160M $820M -9.7% -1.9% CCRN
FY2020 $150M $840M 4.0% -1.1% HDSN
FY2021 $190M $1.68B 21.9% 8.3% HDSN
FY2022 $330M $2.80B 40.4% 9.6% HDSN
FY2023 $290M $2.02B 27.0% 5.6% HDSN
FY2024 $240M $1.34B 12.4% -1.3% HDSN
FY2025 $250M $1.05B 7.5% -8.0% HDSN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HDSN BREAKDOWN
90d in phase · OBV ACCUMULATION
Current IV 79.1%
IV Percentile 15th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact HDSN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CCRN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 11.1%
IV Percentile 4th %ile
Put/Call OI Skew 0.76x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CCRN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HDSN Moat Profile Cyclical / Execution-Driven Positioning
Specialty Chemicals Operator
Competes within the Specialty Chemicals value chain with $186.5M market capitalization and 2.0% operating margin.
OpEx & R&D Reinvestment 19.0% of Rev ($46M)
90D Engineering Disclosures 0 Published
CCRN Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $427.7M market capitalization and -0.8% operating margin.
OpEx & R&D Reinvestment 21.0% of Rev ($210M)
90D Engineering Disclosures 0 Published

Investor FAQ HDSN vs CCRN Key Questions & Quantitative Answers

As of Nov 16, 2026, Hudson Technologies Inc (HDSN) captures the overall head-to-head institutional edge over Cross Country Healthcare Inc (CCRN) on higher Unified Composite conviction (53.2/100 HOLD vs. 52.5/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while CCRN wins 4–2 across the 6-pillar growth and valuation breakdown. HDSN trades at $4.25 (25.9x Forward P/E, 2.0% operating margin) versus CCRN at $13.25 (47.3x Forward P/E, -0.8% operating margin). Growth vs. Quality Trade-Off: HDSN earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. CCRN 52.5/100 HOLD) and 1.32β · 68% Vol risk profile, whereas CCRN leads top-line expansion (-17.8% YoY revenue growth, 12.61x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: HDSN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.9); meanwhile CCRN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 76.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CCRN leads the Growth & Scale pillar: HDSN posts -19.7% YoY revenue growth and -82.0% YoY earnings growth on $242M TTM revenue (21.0% gross margin, 2.0% operating margin), compared with CCRN at -17.8% YoY revenue growth and -78.5% YoY earnings growth on $1.00B TTM revenue (20.2% gross margin, -0.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), HDSN cumulative revenue shifted +47.1% while CCRN shifted +28.0%. In operating R&D and SG&A reinvestment, HDSN deploys 19.0% of Rev ($46M) (0 90-day corporate R&D disclosures) versus 21.0% of Rev ($210M) (0 disclosures) for CCRN.

HDSN screens cheaper on headline valuation multiples. HDSN trades at 25.9x Forward P/E, 16.5x Trailing P/E, 0.29x PEG, and 0.6x EV/Revenue (-13.0% FCF margin), whereas CCRN trades at 47.3x Forward P/E, 126.6x Trailing P/E, 12.61x PEG, and 0.3x EV/Revenue (4.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HDSN (-0.5% ROE) versus CCRN (-27.0% ROE) capital efficiency.

In options market volatility and institutional positioning, HDSN carries 79.1% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 68% Vol realized risk). By comparison, CCRN carries 11.1% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.76x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.50β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.